Fentanyl pharmacokinetics in patients undergoing renal transplantation

Pharmacotherapy

Volumn 17, Issue 4, 1997, Pages 746-752

  Koehntop, Douglas E ^a,c   Rodman, John H ^b  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UMHC Box 294 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; UREA NITROGEN BLOOD LEVEL; UREMIA;

ADJUVANTS, ANESTHESIA; ADOLESCENT; ADULT; ANALGESICS, OPIOID; BIOLOGICAL AVAILABILITY; BLOOD UREA NITROGEN; FEMALE; FENTANYL; HALF-LIFE; HUMANS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; SERUM ALBUMIN; TRIGLYCERIDES;

EID: 0030762608     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hudson RJ, Thomson IR, Cannon JE, Friesen RM, Meatherall RC. Pharmacokinetics of fentanyl in patients undergoing abdominal aortic surgery. Anesthesiology 1986;64:334-8.
2. Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet 1983;8:422-46.
3. Belani KG, Palahniuk RJ. Kidney transplantation. Int Anesthesiol Clin 1991;29:17-39.
4. Bailey PL, Stanley TH. Intravenous opioid anesthetics. In: Miller RD, ed. Anesthesia, 4th ed. New York: Churchill Livingstone, 1994:291-387.
5. Terao N, Shen DD. Reduced extraction of 1-propranolol by perfused rat liver in the presence of uremic blood. J Pharmacol Exp Ther 1985;233:277-84.
6. Bianchetti G, Graziani G, Brancaccio D, et al. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet 1976;1:373-84.
7. Ahmed JH, Grant AC, Rodger RSC, Murray GR, Elliot HL. Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine. Br J Clin Pharmacol 1991;32:57-62.
8. Meuldermans WEG, Hurkmans RMA, Heykants JJP. Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. Arch Int Pharmacodyn 1982;257:4-19.
9. Bower S. Plasma protein binding of fentanyl: the effect of hyperlipoproteinaemia and chronic renal failure. J Pharm Pharmacol 1982;34:102-6.
10. Piafsky KM. Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 1980;5:246-62.
11. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure: in-depth review. Am J Kidney Dis 1993;21:573-92.
12. Haughey DB, Kraft CJ, Matzke GR, Keane WF, Halstenson CE. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. Am J Nephrol 1985;5:35-9.
13. Michaels M, Hendriks R, Heykants J. A sensitive radioimmunoassay for fentanyl plasma level in dogs and man. Eur J Clin Pharmacol 1977;12:153-8.
14. Peck CC, Rodman JH. Analysis of clinical pharmacokinetic data for individualizing drug dosage regimens. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring, 2nd ed. Spokane, WA: Applied Therapeutics, 1986:55-82.
15. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comp Prog Biomed 1979;9:115-34.
16. Fyman PN, Reynolds JR, Moser F, Avitable M, Casthely PA, Butt K. Pharmacokinetics of sufentanil in patients undergoing renal transplantation. Can J Anaesth 1988;35:312-15.
17. Koehntop DE, Noormohamed SE, Fletcher CV. Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation. Pharmacotherapy 1994;14:592-99.
18. Tateishi T, Krivoruk Y, Ueng Y-F, Wood AJJ, Guengerich FP, Wood M. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 1996;82:167-72.
19. Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH. Sufentanil disposition: is it affected by erythromycin administration? Anesthesiology 1993;78:260-5.
20. Shlugman D, Dufore S, Dershwitz M, et al. Respiratory effects of remifentanil in subjects with severe renal impairment compared to matched controls [abstr]. Anesthesiology 1994;81:A1417
21. Egfjord M, Daugaard H, Olgaard K. Effect of uremia on aldosterone metabolism in the isolated perfused rat liver. Metabolism 1993;42:470-6.
22. Bovill JG, Sebel PS, Blackburn CL, Oei-Lim V, Heykants JJ. The pharmacokinetics of sufentanil in surgical patients. Anesthesiology 1984;61:502-6.
23. Wiggum DC, Cork RC, Weldon ST, Gandolfi AJ, Perry DS. Postoperative respiratory depression and elevated sufentanil levels in a patient with chronic renal failure. Anesthesiology 1985;63:708-10.
24. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Philadelphia: Lea & Febiger, 1980:34-47.
25. Danon A, Chen Z. Binding of imipramine to plasma proteins: effect of hyperlipoproteinemia. Clin Pharmacol Ther 1979;25:316-21.
26. Nilsen OG, Leren P, Aakesson I, Jacobsen S. Binding of quinidine in sera with different levels of triglycerides, cholesterol, and orosomucoid protein. Biochem Pharmacol 1978;27:871-6.
27. Henkin Y, Neeman Z, Zuili I, Chaimovitz C, Shany S. The relationship between plasma and dialysate lipoproteins and apoproteins in patients treated by continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993;22:829-34.
28. Goldberg I. Lipometabolism in normal and uremic patients. Am J Kidney Dis 1993;21:87-90.